The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Association Between Increased Estrogen Status and Increased Fibrinolytic Potential in the Framingham Offspring Study
Abstract
Background Although extensive evidence indicates that estrogen is responsible for the markedly decreased cardiovascular risk of premenopausal women, the mechanism through which estrogen might exert its protective effect has not been adequately explained. Since thrombosis is now recognized to play an important role in the onset of cardiovascular disease, we investigated the relation between estrogen status and fibrinolytic potential, a determinant of thrombotic risk. Methods and Results We determined levels of plasminogen activator inhibitor (PAI-1) antigen and tissue plasminogen activator (TPA) antigen in 1431 subjects from the Framingham Offspring Study. Fibrinolytic potential was compared between subjects with high estrogen status (premenopausal women and postmenopausal women receiving hormone replacement therapy) and low estrogen status (men and postmenopausal women not receiving hormone replacement therapy). In all comparisons, subjects with high estrogen status had greater fibrinolytic potential (lower PAI-1 levels) than subjects with low estrogen status. First, postmenopausal women receiving estrogen replacement therapy had lower levels of PAI-1 than those not receiving therapy (13.0±0.5 versus 19.5±1.0 ng/mL, P <.001). Second, premenopausal women had lower levels of PAI-1 than men of a similar age (14.8±0.6 versus 20.3±0.8 ng/mL, P <.001); this sex difference diminished when postmenopausal women not receiving hormone replacement therapy were compared with men of a similar age (19.6±0.7 versus 21.1±0.7 ng/mL, P =.089). Third, premenopausal women had markedly lower levels of PAI-1 antigen than postmenopausal women not receiving estrogen therapy (14.8±0.6 versus 19.5±1.0 ng/mL, P <.001). The between-group differences observed for TPA antigen were similar to those for PAI-1 antigen. Conclusions Each of these comparisons indicates that the cardioprotective effect of estrogen may be mediated, in part, by an increase in fibrinolytic potential. These findings might provide at least a partial explanation for the protection against cardiovascular disease experienced by premenopausal women, and the loss of that protection following menopause.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Warnick, G. R., Benderson, J., & Albers, J. J. (1982) · Clinical Chemistry · doi:10.1093/clinchem/28.6.1379 · Cited by 2,159
Stampfer, M. J., Colditz, G. A., Willett, W. C., Manson, J. E., Rosner, B., Speizer, F. E., & Hennekens, C. H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109123251102 · Cited by 1,997
Circadian Variation in the Frequency of Onset of Acute Myocardial Infarction
Muller, J. E., Stone, P. H., Turi, Z. G., Rutherford, J. D., Czeisler, C. A., Parker, C., Poole, W. K., Passamani, E., Roberts, R., Robertson, T., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198511213132103 · Cited by 1,884
Self-citationAN INVESTIGATION OF CORONARY HEART DISEASE IN FAMILIES
KANNEL, W. B., FEINLEIB, M., McNAMARA, P. M., GARRISON, R. J., & CASTELLI, W. P. (1979) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112813 · Cited by 1,645
Stampfer, M. J., & Colditz, G. A. (1991) · Preventive Medicine · doi:10.1016/0091-7435(91)90006-p · Cited by 1,600
PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION
Hamsten, A., Walldius, G., Szamosi, A., Blombäck, M., Faire, U., Dahlén, G., Landou, C., & Wiman, B. (1987) · The Lancet · doi:10.1016/s0140-6736(87)93050-9 · Cited by 1,474
Bush, T. L., Barrett-Connor, E., Cowan, L. D., Criqui, M. H., Wallace, R. B., Suchindran, C. M., Tyroler, H. A., & Rifkind, B. M. (1987) · Circulation · doi:10.1161/01.cir.75.6.1102 · Cited by 1,346
Hamsten, A., Wiman, B., de Faire, U., & Blombäck, M. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512193132501 · Cited by 1,342
Estrogen and coronary heart disease in women
Barrett-Connor, E. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03460140089033 · Cited by 1,241
Walsh, B. W., Schiff, I., Rosner, B., Greenberg, L., Ravnikar, V., & Sacks, F. M. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110243251702 · Cited by 1,152
Menopause and the Risk of Coronary Heart Disease in Women
Colditz, G. A., Willett, W. C., Stampfer, M. J., Rosner, B., Speizer, F. E., & Hennekens, C. H. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704303161801 · Cited by 1,148
Nabulsi, A. A., Folsom, A. R., White, A., Patsch, W., Heiss, G., Wu, K. K., & Szklo, M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304153281501 · Cited by 906
Menopause and Coronary Heart Disease: The Framingham Study
GORDON, T., KANNEL, W. B., HJORTLAND, M. C., & McNAMARA, P. M. (1978) · Annals of Internal Medicine · doi:10.7326/0003-4819-89-2-157 · Cited by 888
Cardiovascular Health and Disease in Women
Wenger, N. K., Speroff, L., & Packard, B. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307223290406 · Cited by 801
Endogenous tissue-type plasminogen activator and risk of myocardial infarction
Ridker, P. M., Vaughan, D. E., Manson, J., Hennekens, C., & Stampfer, M. (1993) · The Lancet · doi:10.1016/0140-6736(93)90998-v · Cited by 582
Declerck, P., Alessi, M., Verstreken, M., Kruithof, E., Juhan-Vague, I., & Collen, D. (1988) · Blood · doi:10.1182/blood.v71.1.220.220 · Cited by 537
Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions
McNamara, J. R., & Schaefer, E. J. (1987) · Clinica Chimica Acta · doi:10.1016/0009-8981(87)90188-4 · Cited by 521
Metabolic risk factors for coronary heart disease in women: Perspective from the Framingham Study
Kannel, W. B. (1987) · American Heart Journal · doi:10.1016/0002-8703(87)90511-4 · Cited by 458
Plasminogen activator inhibitors: hormonally regulated serpins
Andreasen, P. A., Georg, B., Lund, L. R., Riccio, A., & Stacey, S. N. (1990) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(90)90164-4 · Cited by 398
Progress in Hemostasis and Thrombosis.
(1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-81-1-144_1 · Cited by 348
Stiko-Rahm, A., Wiman, B., Hamsten, A., & Nilsson, J. (1990) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.10.6.1067 · Cited by 298
Cardiovascular protection by oestrogen—a calcium antagonist effect?
Collins, P., Rosano, G. M. C., Jiang, C., Lindsay, D., Poole-Wilson, P. A., & Sarrel, P. M. (1993) · The Lancet · doi:10.1016/0140-6736(93)91158-i · Cited by 269
Type 1 plasminogen activator inhibitor
三室, 淳. (1990) · Medical Entomology and Zoology · Cited by 266
Jansson, J. H., Olofsson, B. O., & Nilsson, T. K. (1993) · Circulation · doi:10.1161/01.cir.88.5.2030 · Cited by 240
Mehta, J., Mehta, P., Lawson, D., & Saldeen, T. (1987) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(87)80373-x · Cited by 239
Coagulation Activation Following Estrogen Administration to Postmenopausal Women
Caine, Y. G., Bauer, K. A., Barzegar, S., ten Cate, H., Sacks, F. M., Walsh, B. W., Schiff, I., & Rosenberg, R. D. (1992) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646283 · Cited by 201
Juhan-Vague, I., Alessi, M. C., Joly, P., Thirion, X., Vague, P., Declerck, P. J., Serradimigni, A., & Collen, D. (1989) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.9.3.362 · Cited by 201
Rånby, M., Bergsdorf, N., Nilsson, T., Mellbring, G., Winblad, B., & Bucht, G. (1986) · Clinical Chemistry · doi:10.1093/clinchem/32.12.2160 · Cited by 192
Plasminogen Activator Inhibitor 1 and Atherothrombosis
Juhan-Vague, I., & Alessi, M. C. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646175 · Cited by 192
Barrett-Connor, E. L., & Laakso, M. (1990) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.10.4.531 · Cited by 157
Huber, K., Rość, D., Resch, I., Schuster, E., Glogar, D. H., Kaindl, F., & Binder, B. R. (1988) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646974 · Cited by 128
Impaired fibrinolysis in coronary artery disease
Francis, R. B., Kawanishi, D. T., Baruch, T., Mahrer, P. R., Rahimtoola, S. H., & Feinstein, D. I. (1988) · American Heart Journal · doi:10.1016/0002-8703(88)90878-2 · Cited by 113
Gram, J., & Jespersen, J. (1987) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651081 · Cited by 104
Hemostatic factors according to menopausal status and use of hormone replacement therapy
Meilahn, E. N., Kuller, L. H., Matthews, K. A., & Kiss, J. E. (1992) · Annals of Epidemiology · doi:10.1016/1047-2797(92)90094-7 · Cited by 90
Verheugt, F. W. A., ten Cate, J. W., Sturk, A., Imandt, L. M. F. M., Verhorst, P. M. J., van Eenige, M. J., Verwey, W., & Roos, J. P. (1987) · The American Journal of Cardiology · doi:10.1016/0002-9149(87)90851-4 · Cited by 81
Estrogen and Cardiovascular Disease
Løbo, R. A. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb30340.x · Cited by 80
Oseroff, A., Krishnamurti, C., Hassett, A., Tang, D. B., & Alving, B. M. (1989) · PubMed · Cited by 73
On the role of coagulation and fibrinolysis in atherosclerosis
Juhan-Vague, I., & Collen, D. (1992) · Annals of Epidemiology · doi:10.1016/1047-2797(92)90092-5 · Cited by 67
Colvin, P. L., Auerbach, B. J., Case, L. D., Hazzard, W. R., & Applebaum-Bowden, D. M. (1991) · Metabolism · doi:10.1016/0026-0495(91)90129-k · Cited by 66
A critical review of the relationship between impaired fibrinolysis and myocardial infarction
Prins, M. H., & Hirsh, J. (1991) · American Heart Journal · doi:10.1016/0002-8703(91)91014-e · Cited by 64
Marckmann, P., Sandström, B., & Jespersen, J. (1992) · Atherosclerosis · doi:10.1016/0021-9150(92)90070-w · Cited by 50
The Impact of Female Hormone Usage on the Lipid Profile
Vaziri, S. M. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410190036005 · Cited by 50
Quehenberger, P., Kapiotis, S., PARTAN, C., Schneider, B., Wenzel, R., Gaiger, A., & Speiser, W. (1993) · Annals of Hematology · doi:10.1007/bf01709663 · Cited by 35
Correlations between fibrinolytic function and acute myocardial infarction
Wiman, B., & Hamsten, A. (1990) · The American Journal of Cardiology · doi:10.1016/0002-9149(90)90397-j · Cited by 34
Studies on the mechanism of action of oral contraceptives with regard to fibrinolytic variables
Kooistra, T., Bosma, P. J., Jespersen, J., & Kluft, C. (1990) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(90)90591-t · Cited by 34
Glucose Tolerance in Women: The Effects of Age, Body Composition, and Sex Hormones
Busby‐Whitehead, M. J., Bellantoni, M. F., Tobin, J. D., Muller, D. C., Kafonek, S. D., Blackman, M. R., & Andres, R. (1992) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1992.tb02018.x · Cited by 15
Cited by
The Protective Effects of Estrogen on the Cardiovascular System
Mendelsohn, M. E., & Karas, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906103402306 · Cited by 3,103
The Emergence of the Metabolic Syndrome with Menopause
Carr, M. C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030242 · Cited by 1,449
“Age-matched men have higher levels of tPA antigen than premenopausal women (73).”
BackgroundA Clinical Trial of Estrogen-Replacement Therapy after Ischemic Stroke
Viscoli, C. M., Brass, L. M., Kernan, W. N., Sarrel, P. M., Suissa, S., & Horwitz, R. I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010534 · Cited by 921
Plasminogen-Activator Inhibitor Type 1 and Coronary Artery Disease
Kohler, H. P., & Grant, P. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006153422406 · Cited by 806
Dubey, R. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00527-2 · Cited by 571
Metadata
- Authors
- Gebara, O. C. E., Mittleman, M. A., Sutherland, P., Lipinska, I., Matheney, T., Xu, P., Welty, F. K., Wilson, P. W. F., Levy, D., Muller, J. E., & Tofler, G. H.
- Venue
- Circulation
- Published
- 1995-04
- Volume
- 91
- Issue
- 7
- Pages
- 1952-1958
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1991977311
- Cited by
- 298
- References
- 47
- FWCI
- 16.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.